ImmunityBio, Inc. (IBRX) Form 8-K — Aug 4, 2026

$IBRXForm 8-KItems 2.02Filed Aug 4, 2026, 7:36 AM ET0001326110-26-000077Original filing

ImmunityBio reported record Q2 2026 net product revenue of $50.7 million, representing a 92% year-over-year increase and the eighth consecutive quarter of sequential growth. This performance was driven by continued adoption of ANKTIVA among U.S. urologists and improved market access. The company ended the quarter with $357.4 million in cash, cash equivalents, and marketable securities, providing a strong financial position to support its operations.

Key figures

Revenue: 50.7 million
Revenue Yoy: 92%
Cash Position: 357.4 million
PDUFA date: January 6, 2027
H1 2026 revenue: 94.8 million
Adjusted net loss: 81.0 million
H1 2026 revenue growth: 121%

Price after filing

1 day: -4.0%7 days: +2.0%30 days: +6.7%

Close on the filing date to close N calendar days later (from $7.45). Historical, not a forecast.

AI analysis

Red flags3 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

Upgrade to Pro · $49/mo billed annually

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.